title: Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
abstract: OBJECTIVE
  To evaluate the MIROX strategy (6 FOLFOX7 cycles followed by 6 FOLFIRI cycles) in patients with resected or resectable metastases from colorectal cancer.
  
  
  METHODS
  This trial compared the MIROX strategy to 12 cycles of simplified LV5FU2 (sLV5FU2). Chemotherapy was perioperative or adjuvant, at the investigator's decision, with stratification for this parameter. The primary objective was disease-free survival (DFS). The trial was interrupted in 2004, following the results of the adjuvant MOSAIC trial showing superiority of FOLFOX4 over LV5FU2.
  
  
  RESULTS
  Thirty-nine patients were included: 20 in MIROX arm and 19 in sLV5FU2 arm. Median DFS was higher in the MIROX arm (not reached versus 24.8 months, P = 0.044). MIROX regimen was well tolerated; 5/20 patients experienced a Grade 3 sensoryneuropathy.
  
  
  CONCLUSIONS
  The MIROX strategy demonstrated promising efficacy, but this must be considered cautiously due to the small number of patients included. The pragmatic approach adopted for the treatment chronology is feasible.
authors.affiliation: Department of Medical Oncology, University Hospital, Lille, France. Mohamed.HEBBAR@CHRU-LILLE.FR
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hebbar
authors.forename: Benoist
authors.initials: B
authors.lastname: Chibaudel
authors.forename: Thierry
authors.initials: T
authors.lastname: André
authors.forename: Christophe
authors.initials: C
authors.lastname: Louvet
authors.forename: Denis
authors.initials: D
authors.lastname: Smith
authors.forename: Laurent
authors.initials: L
authors.lastname: Mineur
authors.forename: Mostepha
authors.initials: M
authors.lastname: Bennamoun
authors.forename: May
authors.initials: M
authors.lastname: Mabro
authors.forename: David
authors.initials: D
authors.lastname: Brusquant
authors.forename: Franck
authors.initials: F
authors.lastname: Bonnetain
authors.forename: François-René
authors.initials: FR
authors.lastname: Pruvot
authors.forename: Aimery
authors.initials: A
authors.lastname: de Gramont
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000077150:Oxaliplatin
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin